ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1820

Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls

Blanka Stiburkova1, Kateřina Pavelcová1, Jana Bohatá1, Karel Pavelka2, Lenka Hasíková1, Jakub Závada1, Aleš Kvasnička3, Dana Dobešová3 and David Friedecký3, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 3Palacky University Olomouc, Olomouc, Czech Republic

Meeting: ACR Convergence 2022

Keywords: Biomarkers, gout, hyperuricemia, metabolomics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of the adult population in the Czech Republic. Currently, it is not possible to predict whether patients with hyperuricemia (HUA) will develop gout, to evaluate the risk of recurrent attacks, or joint damage. Impaired cardiovascular and kidney functions have recently been more precisely described in gout patients. Identification of novel biomarkers of gout pathogenesis is desirable for prevention and risk stratification of groups susceptible to acute attacks of gouty arthritis, development of joint damage, and important comorbidities.

Methods: In this study, a targeted lipidomic analysis consisting of high-performance liquid chromatography coupled with mass spectrometry was used to analyse plasma of clinically and biochemically characterized gout (n=194) and HUA (n=96) patients and a normouricemic control group (n=70), described previously [1, 2]. Statistical analysis included univariate approaches (t‑test, ROC analysis) and multivariate approaches (PCA, OLPS-DA). Data visualization was performed using the Cytoscape software to construct lipidome maps.

References:
1. Horváthová et al. J Clin Med. (2019) 8(11):1965.
2. Bohatá et al. Arthritis Res Ther . (2021) 10;23(1):186.

Results: More than 650 lipids belonging to 20 lipid (sub)classes were measured and semiquantified in plasma. Statistically significant discrimination of the study groups was observed by un/supervised statistical analyses. In patients, increased levels of phosphatidylinositols, phosphatidylethanolamines and phosphatidylcholines were observed. On the other hand, lysophosphatidylcholines (LPC) and their plasmalogens (LPC-O) were decreased in patients. Clinical performance of selected lipid markers exceeded 90% AUC (from ROC) analysis for more than 30 lipids

Conclusion: Our results point to the involvement of multiple glycerophospholipid classes, for instance LPC and LPC-O, in gout pathobiochemistry. To elaborate, a proinflammatory effect of LPC has been described in the pathogenesis of atherosclerosis. LPC‑O can serve as oxygen and radical scavengers via their vinyl ether bond which is reactive to oxygen and nitrogen species in the context of inflammation-induced oxidative stress. These results will help to further understand the pathobiochemical mechanism of gout and HUA, with the potential for early detection of gout-susceptible HUA patients.

Supporting image 1

Figure 1
Multivariate statistical models based on 659 variables (identified lipids). A) Principal component analysis of gout and hyperuricemic (HUA) patients (red) vs. controls (blue) and quality control samples (QC, green), B) OPLS-DA for gout patients (dark red) vs. HUA (dark blue). C) Map of the lipidome of 20 lipid (sub)classes as a comparison between all patients (HUA+Gout) against controls. Each circle symbolizes a unique lipid represented by the change in median (log2 fold change, blue – decreased, red – increased in patients) and AUC value in percentage by increasing size (from ROC analysis) for the group of patients versus controls. Lipids below 85% AUC are not visualized.


Disclosures: B. Stiburkova, None; K. Pavelcová, None; J. Bohatá, None; K. Pavelka, MSD, Pfizer, Roche, Eli Lilly, Medac, UCB, SOBI, Biogen, Sandoz, Viatris; L. Hasíková, None; J. Závada, AbbVie/Abbott, Eli Lilly, Sandoz, Novartis, Egis, UCB; A. Kvasnička, None; D. Dobešová, None; D. Friedecký, None.

To cite this abstract in AMA style:

Stiburkova B, Pavelcová K, Bohatá J, Pavelka K, Hasíková L, Závada J, Kvasnička A, Dobešová D, Friedecký D. Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/targeted-plasma-lipidomics-distinguishes-patients-with-gout-and-hyperuricemia-from-controls/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeted-plasma-lipidomics-distinguishes-patients-with-gout-and-hyperuricemia-from-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology